Shaily Engineering Plastics Limited — PPTs, 12-02-2026: Investor Presentation

Shaily Engineering Plastics delivered strong Q3 & 9M FY26 results. Consolidated revenue rose 27% YoY to Rs. 250.5 Cr in Q3, with PAT jumping 48% YoY to Rs. 37.4 Cr. For 9M, revenue hit Rs. 753.8 Cr (+32% YoY) and PAT more than doubled (+101%) to Rs. 129.8 Cr. Healthcare was the standout performer, growing 139% YoY in Q3.

Strategically, Shaily is expanding its global footprint by setting up a new medical device manufacturing facility in Abu Dhabi (AED 130-150 million investment, operational Q4 FY28). This aims for 75 million pen injectors annually, targeting the GLP-1 segment. Recent wins include 2 new GLP-1 customers & contracts, and new industrial/consumer mandates. Mr. Joe Kam joined as COO (Healthcare) from March 1, 2026.

EBITDA for Q3 grew 43% YoY to Rs. 66.4 Cr (margins up 310 bps to 26.5%). 9M EBITDA surged 76% YoY to Rs. 218.4 Cr (margins up 730 bps to 29.0%). RoCE hit 38.4% & RoE 29.1% (Dec 2025), showing robust capital efficiency. Focus on high-growth segments & global expansion underpins future outlook.